OBJECTIVE -Cardiovascular disease (CVD) is the most important cause of mortality in patients with type 2 diabetes and is preceded by endothelial dysfunction. Flow-mediated dilation (FMD) is a noninvasive technique for measuring endothelial dysfunction. We aimed to determine the effect of long-term statin therapy versus placebo on FMD in patients with type 2 diabetes without manifest CVD.
RESEARCH DESIGN AND METHODS-A randomized, placebo-controlled, doubleblind trial was performed with 250 type 2 diabetic patients. Patients were given 0.4 mg cerivastatin or placebo daily. In August 2001, when cerivastatin was withdrawn from the market, the 0.4 mg cerivastatin was replaced by 20 mg simvastatin, without deblinding the study. The primary end point was the change in FMD, measured by B-mode ultrasound, after 2 years.RESULTS -Determinants of baseline FMD were diabetes duration, common carotid intimamedia thickness, and brachial artery diameter. FMD at baseline was 1.51% in the placebo group and 1.66% in the statin group and did not change significantly after 2 years.CONCLUSIONS -The 2-year statin therapy had no effect on FMD in type 2 diabetes. Statin-induced improvement of cardiovascular risk in patients with type 2 diabetes may be mediated through mechanisms other than increased nitric oxide availability.
Diabetes Care 28:1668 -1674, 2005C ardiovascular disease (CVD) is the most important cause of mortality in patients with type 2 diabetes (1). Endothelial dysfunction precedes the development of atherosclerotic plaques and is believed to be reversible (2). Nitric oxide (NO) is a key molecule in this process. It modulates blood flow and vascular permeability, limits inflammation and coagulation, and diminishes vascular smooth muscle cell proliferation and migration. Type 2 diabetes is associated with endothelial dysfunction; the underlying mechanisms are complex and related to hyperglycemia (sorbitol, hexosamine, protein kinase C, and advanced glycation end product pathways) and insulin resistance, resulting in mitochondrial superoxide overproduction and thus decreased NO availability (3). Regarding insulin, its vasodilatory capacity is at least in part NO dependent (4,5), thus explaining how insulin resistance might be related to endothelial dysfunction.Flow-mediated dilation (FMD) of the brachial artery is a noninvasive technique for measuring endothelial function. FMD of the brachial artery has been shown to be the result of endothelium-derived NO release (6) and is related to coronary vasoreactivity (7). FMD has proven to be predictive for the presence of coronary artery disease (8,9), for future cardiovascular events (10 -12), and for postoperative cardiovascular events (13) in high-risk populations. Improvement in FMD predicts a favorable cardiovascular outcome in postmenopausal hypertensive women (2). However, in patients at lower risk, FMD was not independently associated with outcome (14). FMD is impaired in patients with type 2 diabetes with reported FMD values of 4.47-12.3% in control subjects vs. 2.96 -6.1...